search
Back to results

Clinical Trial of "Magic Gyno" Laser Device

Primary Purpose

Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital

Status
Recruiting
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Laser treatment
Blood test
Clinical urine test
Vaginal smear
Pelvic ultrasound
Female Sexual Function Index
International Consultation on Incontinence Questionnaire - Short Form
The Short Form Health Survey
Vaginal Health Index
Vital signs determination
pH of vagina determination
Physical parameters determination
Sponsored by
MeLSyTech, Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Female Urogenital Diseases focused on measuring Laser, Vaginal, Neodymium Laser, Laser Treatment, Nanosecond, Female Urogenital Diseases, Pelvic Organ Prolapse

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women from 18 years old in conditions caused by collagen deficiency in the treated area, women in premenopause and menopause;
  • Participants who signed informed consent and fully informed about the purpose of the study;

Following disorders:

  • Stress urinary incontinence,
  • Mixed urinary incontinence with a predominance of the stress component,
  • Genitourinary menopausal syndrome,
  • Dystrophic and atrophic processes in the genital area,
  • Scleroatrophic changes in the urogenital region,
  • Prolapse of the genitals I-II degree,
  • Vaginal relaxation syndrome,
  • Postpartum recovery,
  • Sexual dysfunctions,
  • Restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes),
  • Preoperative preparation for genital prolapse surgery and postoperative rehabilitation.

Exclusion Criteria:

  • Age up to 18 years;
  • Inability or unwillingness to give informed consent to participate in a trial or to fulfill the requirements of a clinical trial;
  • The presence of contraindications to the use of a medical device;
  • Pregnancy;
  • Bleeding disorders accompanied by a violation of blood clotting;
  • Use of anticoagulant medicines (post-infarction and post-stroke conditions);
  • Autoimmune diseases;
  • Emerging infection diseases of any etiology;
  • Damage to the skin (mucous membranes) in the area of laser treatment;
  • Oncological diseases, cancer alertness;
  • Decompensated diabetes;
  • Photosensitizing drug administration;
  • Decompensated somatic diseases;
  • Decompensated cardiovascular disease, and other decompensated common diseases;
  • Severe somatic diseases (heart failure, chronic renal failure, hepatitis, liver cirrhosis);
  • Severe autoimmune diseases (including hemorrhagic vasculitis);
  • Immunodeficiency (including HIV infection and AIDS);
  • Severe mental and neurological disorders;
  • Bedridden and immobile patients;
  • COVID 19;
  • Acute inflammatory diseases of the urogenital area;
  • Acute purulent processes of the urogenital region;
  • Bleeding of a natural nature (menstruation) and any other types of bleeding in the urogenital area;
  • Postoperative scars up to 6 months;
  • Lateral cysts of the vagina;
  • Growing uterine fibroid;
  • Fillers / suture in the area of laser exposure;
  • The presence of varicose veins of the urogenital region and dilated capillary plexuses of the mucosa.

Sites / Locations

  • Tver State Medical AcademyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Genitourinary disorder

Relaxation of vagina

Arm Description

Participants with: stress urinary incontinence, mixed urinary incontinence with a predominance of the stress component, genitourinary menopausal syndrome, dystrophic and atrophic processes in the genital area, scleroatrophic changes in the urogenital region. Laser treatment of the vagina, vulva, and paraurethral region with "Magic Gyno" laser. In total, three procedures will be performed with an interval of 4 weeks. During the procedure, the following sequence of actions will be performed: st Stage - vaginal processing with a conical mirror handpiece, nd Stage - vaginal processing with a corner mirror handpiece, d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.

Participants with: prolapse of the genitals I-II degree, vaginal relaxation syndrome, postpartum recovery, sexual dysfunctions, restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes), preoperative preparation for genital prolapse surgery and postoperative rehabilitation. Laser treatment of the vagina, vulva, and paraurethral region with "Magic Gyno" laser. In total, three procedures will be performed with an interval of 4 weeks. During the procedure, the following sequence of actions will be performed: st Stage - vaginal processing with a conical mirror handpiece, nd Stage - vaginal processing with a corner mirror handpiece, d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.

Outcomes

Primary Outcome Measures

Mean Change from Baseline of Vaginal Health Index Score
Vaginal Health Index will be investigated by clinical examination for vagina: A. Vaginal elasticity (Characteristic=Points: None=1, Poor=2, Fair=3, Good=4, Excellent=5), B. Vaginal secretions (None=1; Sсant, thin yellow=2; Superficial, thin white=3; Moderate, thin white=4; Normal (white)=5), C. Epithelial mucous membrane (Petechiae noted before contact=1, Bleeding with light contact=2, Bleeds with scraping=3, Not friable thin epithelium=4, Normal=5), D. Vaginal hydration (None, surface inflamed=1, None, surface nod inflamed=2, Minimal=3, Moderate=4, Normal=5), E. pH will be investigated by test-lines paper (≥6.1=1, 5.6-6.0=2, 5.1-5.5=3, 4.7-5.0=4, ≤4.6=5). Score=A+B+C+D+E

Secondary Outcome Measures

Mean Change from Baseline of "Desire" Score on the Female Sexual Function Index Questionnaire
Participants answer questions: Q1. Over the past 4 weeks, how often did you feel sexual desire or interest? Answers = Points: almost always or always (5), most times (more than half the time) (4), sometimes (about half the time) (3), a few times (less than half the time) (2), almost never or never (1). Q2. Over the past 4 weeks, how would you rate your level (degree) of sexual desire or interest? Answers = Points: very high (5), high (4), moderate (3), low (2), very low or none at all (1) Score = (Score to Q1 + Score to Q2)x0.6
Mean Change from Baseline of "Arousal" Score on the Female Sexual Function Index Questionnaire
Participants answer questions: Q3. Over the past 4 weeks, how often did you feel sexually aroused during sexual activity or intercourse? Q6. Over the past 4 weeks, how often have you been satisfied with your arousal (excitement) during sexual activity or intercourse? Answers = Points (Q3 and Q6): no sexual activity (0), almost always or always (5), most times (4), sometimes (3), a few times (2), almost never or never (1) Q4. Over the past 4 weeks, how would you rate your level of sexual arousal during sexual activity or intercourse? Answers = Points: no sexual activity (0), very high (5), high (4), moderate (3), low (2), very low or none at all (1) Q5. Over the past 4 weeks, how confident were you about becoming sexually aroused during sexual activity or intercourse? Answers=Points: no sexual activity (0), very high confidence (5), high confidence (4), moderate confidence (3), low confidence (2), very low or no confidence (1) Score=(Score to Q3+Score to Q4+Score to Q5+Score to Q6)x0.3
Mean Change from Baseline of "Lubrication" Score on the Female Sexual Function Index Questionnaire
Participants answer questions:Q7. Over the past 4 weeks, how often did you become lubricated ("wet") during sexual activity or intercourse?Q9. Over the past 4 weeks, how often did you maintain your lubrication ("wetness") until completion of sexual activity or intercourse?Answers = Points: no sexual activity (0), almost always or always (5), most times (more than half the time) (4), sometimes (about half the time) (3), a few times (less than half the time) (2), almost never or never (1). Q8. Over the past 4 weeks, how difficult was it to become lubricated ("wet") during sexual activity or intercourse? Q10. Over the past 4 weeks, how difficult was it to maintain your lubrication ("wetness") until completion of sexual activity or intercourse? Answers = Points: no sexual activity (0), extremely difficult or impossible (1), very difficult (2), difficult (3), slightly difficult (4), not difficult (5). Score = (Score to Q7 + Score to Q8 + Score to Q9 + Score to Q10)x0.3
Mean Change from Baseline of "Orgasm" Score on the Female Sexual Function Index Questionnaire
Participants answer questions: Q11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you reach orgasm (climax)? Answers = Points: no sexual activity (0), almost always or always (5), most times (4), sometimes (3), a few times (2), almost never or never (1). Q12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how difficult was it for you to reach orgasm (climax)? Answers = Points: no sexual activity (0), extremely difficult or impossible (1), very difficult (2), difficult (3), slightly difficult (4), not difficult (5). Q13. Over the past 4 weeks, how satisfied were you with your ability to reach orgasm (climax) during sexual activity or intercourse? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Score = (Score to Q11 + Score to Q12 + Score to Q13)x0.4
Mean Change from Baseline of "Satisfaction" Score on the Female Sexual Function Index Questionnaire
Participants answer questions: Q14. Over the past 4 weeks, how satisfied have you been with the amount of emotional closeness during sexual activity between you and your partner? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Q15. Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Q16. Over the past 4 weeks, how satisfied have you been with your overall sexual life? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Score = (Score to Q14 + Score to Q15 + Score to Q16)x0.4
Mean Change from Baseline of "Pain" Score on the Female Sexual Function Index Questionnaire
Participants answer questions: Q17. Over the past 4 weeks, how often did you experience discomfort or pain during vaginal penetration? Answers = Points: did not attempt intercourse (0), almost always or always (1), most times (2), sometimes (3), a few times (4), almost never or never (5). Q18. Over the past 4 weeks, how often did you experience discomfort or pain following vaginal penetration? Answers = Points: did not attempt intercourse (0), almost always or always (1), most times (2), sometimes (3), a few times (4), almost never or never (5). Q19. Over the past 4 weeks, how would you rate your level (degree) of discomfort or pain during or following vaginal penetration? Answers = Points: did not attempt intercourse (0)very high (1)high (2)moderate (3)low (4)very low or none at all (5). Score = (Score to Q17 + Score to Q18 + Score to Q19)x0.4
Mean Change from Baseline of Total Score on International Consultation on Incontinence Questionnaire - Short Form
Participants answer questions: Q1 How often do you leak urine? Answers = Points: never (0), about once a week or less often (1), two or three times a week (2), about once a day (3), several times a day (4), all the time (5). Q2 How much urine do you usually leak? Answers = Points: none (0), a small amount (2), a moderate amount (4), a large amount (6) Q3 How much does leaking urine interfere with your everyday life? Answers = Visual Analogue Scale, where Not at all (0), A great deal (10). Total Score = Scores(Q1+Q2+Q3)
Mean Change from Baseline of "Physical Health Component Score" on The Short Form Health Survey
Participants fill out a survey form (standard RAND 36-Item Health Survey (Version 1.0)). Calculations of final scores (PCS and MCS) will be carried out using Mean and SD from US adult population (PCS-US and MCS-US respectively).
Mean Change from Baseline of "Mental Health Component Score" on The Short Form Health Survey
Participants fill out a survey form (standard RAND 36-Item Health Survey (Version 1.0)). Calculations of final scores (PCS and MCS) will be carried out using Mean and SD form US adult population (PCS-US and MCS-US respectively).
Mean Change from Baseline of pH of vagina
Potential of hydrogen (pH) will be investigated by test-lines paper.
Mean Change from Baseline of Lactobacilli quantity
Smear will be sampled from the posterior wall of vagina and stained according to Gram. Evaluation of the Lactobacilli quantity will be performed for each participant with light microscope in field of view. Score depends on the number of bacteria: low - 1, average - 2, normal - 3.

Full Information

First Posted
July 14, 2022
Last Updated
October 23, 2023
Sponsor
MeLSyTech, Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05463081
Brief Title
Clinical Trial of "Magic Gyno" Laser Device
Official Title
Clinical Trial of the Safety and Efficacy of Medical Device "Laser Medical Device "Magic Gyno""
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 5, 2022 (Actual)
Primary Completion Date
August 28, 2023 (Actual)
Study Completion Date
January 25, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MeLSyTech, Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose. To assess the condition of the vaginal walls and vulva before and after laser treatment, the following methods will be used: gynecology examination, vaginal health index, clinical blood test, vaginal flora examination, vaginal pH. International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF), Female Sexual Function Index (FSFI) and The Short Form Health Survey (SF-36) will be used to collect feedback on changes in the participants life quality. Total up to 70 participants with pathology of pelvic organs will be involved in the study. Participants will be divided into two groups: group with genitourinary symptoms and group with vaginal relaxation symptoms, by 35 participants in each. The time intervals between tests will be the same for both groups. The main hypothesis of the study is improvement in condition of the vaginal walls after laser treatment compared with the condition before treatment.
Detailed Description
The principle of participant distribution into groups is the character of vaginal walls and vulva pathology. Total up to 70 participants will be involved in the study. Participants will be divided into two groups: group with genitourinary symptoms and group with vaginal relaxation symptoms by 35 participants in each. The types of examination of each group are the same and include: General methods: demographic data determination, vital signs determination, gynecological examination, physical examination, clinical blood analysis with glucose determination, clinical urine test, vaginal smear for flora and oncocytology, pelvic ultrasound. Special methods: vaginal smear for flora, vaginal pH determination, filling out the questionnaire (Female Sexual Function Index, International Consultation on Incontinence Questionnaire - Short Form, The Short Form Health Survey), Vaginal Health Index determination. The treatment procedure of this study is the laser treatment of the vagina and vulva with a "Magic Gyno" laser with subsequent monitoring. Treatment Technique: Laser treatment procedure will be carried out in three stages. In total, three procedures will be performed with an interval of 4-6 weeks. One follow-up visit will follow: 90 days after the last procedure. During the procedure, the following sequence of actions will be performed: st Stage - vaginal processing with a conical mirror handpiece, nd Stage - vaginal processing with a corner mirror handpiece, rd Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece. Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 nanoseconds (ns), the pause between pulses is 30 microseconds (us). The energy of one pulse is about 1 millijoule (mJ). The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth. Participants of all groups will be tested with the general methods necessary to include the participant in the study at the first visit. For both group: Studies will be carried out using special methods and then laser treatment of the vagina and vulva and paraurethral region will be performed during the 2nd, 3d, and 4th visits. Studies with all special methods will be performed during the 1st (to include participant in the study), 2nd (before the first treatment), 4th (before the last treatment) and 5th (90 days after the last treatment) visits. Thus, direct comparison between participants condition before and 90 days after treatment within each group will be carried out. The study will be carried out with the participation of Tver State Medical Academy. All data obtained during the study will be transferred to the manufacturer of "MeLSyTech" Ltd. The study will be monitored by "MeLSyTech" Ltd as follows: In the start of study to ensure awareness of researchers about the plan, the rules for filling in case research forms, work with the device. Once a 3 month, monitoring of provided documents (copies of individual registration records of participants (case research forms), informed consent, test results) for the complete filling of the forms; the clarity of filling out forms, the possibility of systematizing information from the forms of their assessment. Monitoring will be conducted with a coordinator visit of the research center and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. In the end of study monitoring will be conducted with a coordinator visit of the research center and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. The investigator submits a clinical evaluation report to the sponsor. Statistics The analysis will be carried out within groups at different time intervals (analysis of matched groups). Before performing statistical analysis of the data, the distribution type of the variables will be assessed. To assess the normality of distribution for each variable, histograms of frequency distributions will be visually evaluated, indicators of skewness, kurtosis, and the D'Agostino-Pearson normality test will be used. In addition to checking the type of distribution of variables, the equality of variances of the studied groups will be assessed using the methods of analysis of variance, in particular the Brown-Forsythe test. Methods of descriptive analysis will be used depending on the type of distribution of the variable. With a normal distribution, the mean (M) and standard deviation (SD) will be calculated. In case of an nongaussian distribution, the median (Me) and interquartile range will be calculated. Different algorithms of statistical analysis will be applied depending on the type of distribution of variables. Comparison of the paired groups with a normal distribution, in case of the equality of the variances, will be carried out by the methods of analysis of variance ANOVA. Comparison of groups in pairs will be performed using the post-hoc method of posterior multiple comparisons (Tukey test). Comparison of groups in which variables do not follow the normal distribution will be carried out using the methods of nonparametric analysis of variations: the Friedman test for matched groups. Differences will be considered statistically significant if the significance P values are <0.05.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital, Menopausal Syndrome, Postmenopausal Period, Vaginal Atrophy, Vaginal Prolapse, Postpartum Period, Sexual Dysfunction, Preoperative Care, Postoperative Care
Keywords
Laser, Vaginal, Neodymium Laser, Laser Treatment, Nanosecond, Female Urogenital Diseases, Pelvic Organ Prolapse

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Genitourinary disorder
Arm Type
Experimental
Arm Description
Participants with: stress urinary incontinence, mixed urinary incontinence with a predominance of the stress component, genitourinary menopausal syndrome, dystrophic and atrophic processes in the genital area, scleroatrophic changes in the urogenital region. Laser treatment of the vagina, vulva, and paraurethral region with "Magic Gyno" laser. In total, three procedures will be performed with an interval of 4 weeks. During the procedure, the following sequence of actions will be performed: st Stage - vaginal processing with a conical mirror handpiece, nd Stage - vaginal processing with a corner mirror handpiece, d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.
Arm Title
Relaxation of vagina
Arm Type
Experimental
Arm Description
Participants with: prolapse of the genitals I-II degree, vaginal relaxation syndrome, postpartum recovery, sexual dysfunctions, restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes), preoperative preparation for genital prolapse surgery and postoperative rehabilitation. Laser treatment of the vagina, vulva, and paraurethral region with "Magic Gyno" laser. In total, three procedures will be performed with an interval of 4 weeks. During the procedure, the following sequence of actions will be performed: st Stage - vaginal processing with a conical mirror handpiece, nd Stage - vaginal processing with a corner mirror handpiece, d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.
Intervention Type
Device
Intervention Name(s)
Laser treatment
Intervention Description
Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ. General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s. The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth.
Intervention Type
Diagnostic Test
Intervention Name(s)
Blood test
Intervention Description
Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
Intervention Type
Diagnostic Test
Intervention Name(s)
Clinical urine test
Intervention Description
Urine sampling for Clinical urine test (to include the participant in the study).
Intervention Type
Diagnostic Test
Intervention Name(s)
Vaginal smear
Intervention Description
Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
Intervention Type
Diagnostic Test
Intervention Name(s)
Pelvic ultrasound
Intervention Description
Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
Intervention Type
Other
Intervention Name(s)
Female Sexual Function Index
Intervention Description
Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Intervention Type
Other
Intervention Name(s)
International Consultation on Incontinence Questionnaire - Short Form
Intervention Description
International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
Intervention Type
Other
Intervention Name(s)
The Short Form Health Survey
Intervention Description
The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
Intervention Type
Diagnostic Test
Intervention Name(s)
Vaginal Health Index
Intervention Description
Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
Intervention Type
Diagnostic Test
Intervention Name(s)
Vital signs determination
Intervention Description
Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
Intervention Type
Diagnostic Test
Intervention Name(s)
pH of vagina determination
Intervention Description
Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
Intervention Type
Diagnostic Test
Intervention Name(s)
Physical parameters determination
Intervention Description
Physical parameters determination (body weight, age, height, body mass index).
Primary Outcome Measure Information:
Title
Mean Change from Baseline of Vaginal Health Index Score
Description
Vaginal Health Index will be investigated by clinical examination for vagina: A. Vaginal elasticity (Characteristic=Points: None=1, Poor=2, Fair=3, Good=4, Excellent=5), B. Vaginal secretions (None=1; Sсant, thin yellow=2; Superficial, thin white=3; Moderate, thin white=4; Normal (white)=5), C. Epithelial mucous membrane (Petechiae noted before contact=1, Bleeding with light contact=2, Bleeds with scraping=3, Not friable thin epithelium=4, Normal=5), D. Vaginal hydration (None, surface inflamed=1, None, surface nod inflamed=2, Minimal=3, Moderate=4, Normal=5), E. pH will be investigated by test-lines paper (≥6.1=1, 5.6-6.0=2, 5.1-5.5=3, 4.7-5.0=4, ≤4.6=5). Score=A+B+C+D+E
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Secondary Outcome Measure Information:
Title
Mean Change from Baseline of "Desire" Score on the Female Sexual Function Index Questionnaire
Description
Participants answer questions: Q1. Over the past 4 weeks, how often did you feel sexual desire or interest? Answers = Points: almost always or always (5), most times (more than half the time) (4), sometimes (about half the time) (3), a few times (less than half the time) (2), almost never or never (1). Q2. Over the past 4 weeks, how would you rate your level (degree) of sexual desire or interest? Answers = Points: very high (5), high (4), moderate (3), low (2), very low or none at all (1) Score = (Score to Q1 + Score to Q2)x0.6
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Arousal" Score on the Female Sexual Function Index Questionnaire
Description
Participants answer questions: Q3. Over the past 4 weeks, how often did you feel sexually aroused during sexual activity or intercourse? Q6. Over the past 4 weeks, how often have you been satisfied with your arousal (excitement) during sexual activity or intercourse? Answers = Points (Q3 and Q6): no sexual activity (0), almost always or always (5), most times (4), sometimes (3), a few times (2), almost never or never (1) Q4. Over the past 4 weeks, how would you rate your level of sexual arousal during sexual activity or intercourse? Answers = Points: no sexual activity (0), very high (5), high (4), moderate (3), low (2), very low or none at all (1) Q5. Over the past 4 weeks, how confident were you about becoming sexually aroused during sexual activity or intercourse? Answers=Points: no sexual activity (0), very high confidence (5), high confidence (4), moderate confidence (3), low confidence (2), very low or no confidence (1) Score=(Score to Q3+Score to Q4+Score to Q5+Score to Q6)x0.3
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Lubrication" Score on the Female Sexual Function Index Questionnaire
Description
Participants answer questions:Q7. Over the past 4 weeks, how often did you become lubricated ("wet") during sexual activity or intercourse?Q9. Over the past 4 weeks, how often did you maintain your lubrication ("wetness") until completion of sexual activity or intercourse?Answers = Points: no sexual activity (0), almost always or always (5), most times (more than half the time) (4), sometimes (about half the time) (3), a few times (less than half the time) (2), almost never or never (1). Q8. Over the past 4 weeks, how difficult was it to become lubricated ("wet") during sexual activity or intercourse? Q10. Over the past 4 weeks, how difficult was it to maintain your lubrication ("wetness") until completion of sexual activity or intercourse? Answers = Points: no sexual activity (0), extremely difficult or impossible (1), very difficult (2), difficult (3), slightly difficult (4), not difficult (5). Score = (Score to Q7 + Score to Q8 + Score to Q9 + Score to Q10)x0.3
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Orgasm" Score on the Female Sexual Function Index Questionnaire
Description
Participants answer questions: Q11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you reach orgasm (climax)? Answers = Points: no sexual activity (0), almost always or always (5), most times (4), sometimes (3), a few times (2), almost never or never (1). Q12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how difficult was it for you to reach orgasm (climax)? Answers = Points: no sexual activity (0), extremely difficult or impossible (1), very difficult (2), difficult (3), slightly difficult (4), not difficult (5). Q13. Over the past 4 weeks, how satisfied were you with your ability to reach orgasm (climax) during sexual activity or intercourse? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Score = (Score to Q11 + Score to Q12 + Score to Q13)x0.4
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Satisfaction" Score on the Female Sexual Function Index Questionnaire
Description
Participants answer questions: Q14. Over the past 4 weeks, how satisfied have you been with the amount of emotional closeness during sexual activity between you and your partner? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Q15. Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Q16. Over the past 4 weeks, how satisfied have you been with your overall sexual life? Answers = Points: no sexual activity (0), very satisfied (5), moderately satisfied (4), about equally satisfied and dissatisfied (3), moderately dissatisfied (2), very dissatisfied (1). Score = (Score to Q14 + Score to Q15 + Score to Q16)x0.4
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Pain" Score on the Female Sexual Function Index Questionnaire
Description
Participants answer questions: Q17. Over the past 4 weeks, how often did you experience discomfort or pain during vaginal penetration? Answers = Points: did not attempt intercourse (0), almost always or always (1), most times (2), sometimes (3), a few times (4), almost never or never (5). Q18. Over the past 4 weeks, how often did you experience discomfort or pain following vaginal penetration? Answers = Points: did not attempt intercourse (0), almost always or always (1), most times (2), sometimes (3), a few times (4), almost never or never (5). Q19. Over the past 4 weeks, how would you rate your level (degree) of discomfort or pain during or following vaginal penetration? Answers = Points: did not attempt intercourse (0)very high (1)high (2)moderate (3)low (4)very low or none at all (5). Score = (Score to Q17 + Score to Q18 + Score to Q19)x0.4
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of Total Score on International Consultation on Incontinence Questionnaire - Short Form
Description
Participants answer questions: Q1 How often do you leak urine? Answers = Points: never (0), about once a week or less often (1), two or three times a week (2), about once a day (3), several times a day (4), all the time (5). Q2 How much urine do you usually leak? Answers = Points: none (0), a small amount (2), a moderate amount (4), a large amount (6) Q3 How much does leaking urine interfere with your everyday life? Answers = Visual Analogue Scale, where Not at all (0), A great deal (10). Total Score = Scores(Q1+Q2+Q3)
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Physical Health Component Score" on The Short Form Health Survey
Description
Participants fill out a survey form (standard RAND 36-Item Health Survey (Version 1.0)). Calculations of final scores (PCS and MCS) will be carried out using Mean and SD from US adult population (PCS-US and MCS-US respectively).
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of "Mental Health Component Score" on The Short Form Health Survey
Description
Participants fill out a survey form (standard RAND 36-Item Health Survey (Version 1.0)). Calculations of final scores (PCS and MCS) will be carried out using Mean and SD form US adult population (PCS-US and MCS-US respectively).
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of pH of vagina
Description
Potential of hydrogen (pH) will be investigated by test-lines paper.
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)
Title
Mean Change from Baseline of Lactobacilli quantity
Description
Smear will be sampled from the posterior wall of vagina and stained according to Gram. Evaluation of the Lactobacilli quantity will be performed for each participant with light microscope in field of view. Score depends on the number of bacteria: low - 1, average - 2, normal - 3.
Time Frame
1st visit (initial screening); 2nd visit (before the first treatment, no latter 2 months after 1st visit), 4th visit (before the last treatment, 8-12 weeks after 2nd visit); 5th visit (90 days after the last treatment - 4th visit)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women from 18 years old in conditions caused by collagen deficiency in the treated area, women in premenopause and menopause; Participants who signed informed consent and fully informed about the purpose of the study; Following disorders: Stress urinary incontinence, Mixed urinary incontinence with a predominance of the stress component, Genitourinary menopausal syndrome, Dystrophic and atrophic processes in the genital area, Scleroatrophic changes in the urogenital region, Prolapse of the genitals I-II degree, Vaginal relaxation syndrome, Postpartum recovery, Sexual dysfunctions, Restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes), Preoperative preparation for genital prolapse surgery and postoperative rehabilitation. Exclusion Criteria: Age up to 18 years; Inability or unwillingness to give informed consent to participate in a trial or to fulfill the requirements of a clinical trial; The presence of contraindications to the use of a medical device; Pregnancy; Bleeding disorders accompanied by a violation of blood clotting; Use of anticoagulant medicines (post-infarction and post-stroke conditions); Autoimmune diseases; Emerging infection diseases of any etiology; Damage to the skin (mucous membranes) in the area of laser treatment; Oncological diseases, cancer alertness; Decompensated diabetes; Photosensitizing drug administration; Decompensated somatic diseases; Decompensated cardiovascular disease, and other decompensated common diseases; Severe somatic diseases (heart failure, chronic renal failure, hepatitis, liver cirrhosis); Severe autoimmune diseases (including hemorrhagic vasculitis); Immunodeficiency (including HIV infection and AIDS); Severe mental and neurological disorders; Bedridden and immobile patients; COVID 19; Acute inflammatory diseases of the urogenital area; Acute purulent processes of the urogenital region; Bleeding of a natural nature (menstruation) and any other types of bleeding in the urogenital area; Postoperative scars up to 6 months; Lateral cysts of the vagina; Growing uterine fibroid; Fillers / suture in the area of laser exposure; The presence of varicose veins of the urogenital region and dilated capillary plexuses of the mucosa.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ksenia V Shatilova, Ph.D.
Phone
+79262792700
Email
shatilova@melsytech.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vladislav V Dubenskij, Ph.D.
Organizational Affiliation
Tver State Medical Academy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tver State Medical Academy
City
Tver
State/Province
Tver Oblast
ZIP/Postal Code
170036
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vladislav V Dubenskij, Ph.D.
Phone
+7 961 016 00 00
Email
79610160000@yandex.ru

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The following data can be shared with researchers upon an official request: The final version of the Study Protocol approved by the Local Ethics Committee; Copies of anonymized filled Individual Registration Cards (IRC); Informed Consent Form (ICF); Clinical Study Report (CSR) and/or published article (if not contradict the rules and conditions of a journal); Supplement files systematizing data.
IPD Sharing Time Frame
IPD can be shared with researchers starting 3 months after CSR or article publication for five years.
IPD Sharing Access Criteria
IPD can be shared with researchers only upon an official request from researcher's affiliation institution in the letter form on organization's letterhead paper signed by an authorized person. Official request must be directed by e-mail to the contact person (Ksenia Shatilova, shatilova@melsytech.com). The letter must contain the request purpose and statement of internal IPD use as confidential information only. IPD will be shared after approval by CEO of "MeLSyTech" Ltd according to the company internal rules. A requester will be notified of the decision by official letter. Depending on the decision, a requester will receive a link to the repository, or a justified rejection.

Learn more about this trial

Clinical Trial of "Magic Gyno" Laser Device

We'll reach out to this number within 24 hrs